Tubulis closes upsized €128 million Series B2

"This substantial financing from a syndicate of global specialist biotech investors recognizes Tubulis’ unique position in the ADC space"

18-Mar-2024 - Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led byEQT Life Sciences and Nextech Invest Ltd, on behalf of one or more funds managed by it, with participation from new US-based funds, Frazier Life ...

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

"DISCO is uniquely positioned to transform cancer care"

18-Jan-2024 - DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...

iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer

06-Sep-2023 - iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth. Dr. Debus is an ...

CatalYm Closes EUR 50 Million Series C Financing

Start-up develops a "new anti-cancer immunotherapeutic drug with the potential to transform the immuno-oncology landscape"

24-Nov-2022 - CatalYm announced the close of a EUR50 million (USD49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, ...

Indivumed and CELLphenomics Announce Partnership for Improved Cancer Patient Care

European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types

12-Sep-2022 - Indivumed GmbH and CELLphenomics GmbH announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to ...

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours

21-Jun-2022 - Spirea Limited, a Cambridge company created to advance a new generation of antibody drug conjugate (ADC) therapeutics, has announced that it has secured funding of £2.4 million ($3M) with investments from high-profile UK and US investors. Spirea will use the funds to initiate its pipeline of ...

The two startups NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics

19-Jan-2022 - NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...

iOmx Therapeutics raises EUR 65 million in Series B round

The new funds will be used to advance iOmx´ lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology

08-Oct-2021 - iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million. The financing was co-led by Athos Service GmbH – the Strüngmann family office – and MIG ...

New ways for controlled drug activation

A completely new approach - Ultrasound for drug activation

02-Feb-2021 - Researchers at the DWI - Leibniz Institute for Interactive Materials have succeeded in developing a completely new system for activating pharmaceutical agents. The unique feature: Their method is based on the use of ultrasonic waves. The drugs are enclosed in carrier molecules. The ultrasound ...

Sanofi offers to acquire Kiadis

Adds proprietary next generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease therapies

02-Nov-2020 - Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of ...